Experimental cancer drug trial halted early

NCT ID NCT06487858

Terminated Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new experimental drug called BGB-R046, given alone or with another drug (tislelizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Guangxi Medical University Cancer Hospital

Nanning, Guangxi, 530021, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Jining No1 Peoples Hospital West Branch

Jining, Shandong, 272000, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110001, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.